期刊文献+

Nonpeptide somatostatin analogs:recent advances in its application and research 被引量:1

Nonpeptide somatostatin analogs:recent advances in its application and research
暂未订购
导出
摘要 Along with its wide anatomical distribution, somatostatin (SST) acts on multiple targets via a family of 5 receptors to produce a broad spectrum of biological effects. Therefore, a variety of peptide analogs have been produced and are widely used in clinical treatment. However, because of their flaws in the structure of peptide, the clinical efficacy is limited. In this review, we summarize the structure, pharmacological effects and the potential clinical value of non-peptide SST analogs. We focus on the research and development of non-peptide SST analogs since 1998, and discuss the problems and potential prospects for non-peptide SST analogs. We believe that as more non-peptide somatostatin analogs are successfully developed, the extensive clinical application of SSTs will contribute a great deal to medical science. Along with its wide anatomical distribution, somatostatin (SST) acts on multiple targets via a family of 5 receptors to produce a broad spectrum of biological effects. Therefore, a variety of peptide analogs have been produced and are widely used in clinical treatment. However, because of their flaws in the structure of peptide, the clinical efficacy is limited. In this review, we summarize the structure, pharmacological effects and the potential clinical value of non-peptide SST analogs. We focus on the research and development of non-peptide SST analogs since 1998, and discuss the problems and potential prospects for non-peptide SST analogs. We believe that as more non-peptide somatostatin analogs are successfully developed, the extensive clinical application of SSTs will contribute a great deal to medical science.
出处 《Journal of Medical Colleges of PLA(China)》 CAS 2008年第6期364-376,共13页 中国人民解放军军医大学学报(英文版)
关键词 Nonpeptide somatostatin STRUCTURE Pharmacological study Potential clinical value 生长激素抑制素 结构 药理学 临床价值
  • 相关文献

参考文献1

二级参考文献5

  • 1Madeiral I, Ruszniewski P. Digestive system carcinoid tumors: treatment. Rev Med Interne, 1999, 20:421-426.
  • 2Roskams T, Libbrecht L, Van Damme B, et al. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? J Pathol,2000,191 : 150-153.
  • 3Nago M, Nakajima Y, Hisanaga M, et al. The alteration of receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology, 1999,30:413-421.
  • 4王春晖,唐承薇,汤丽平.奥曲肽抑制肝癌生长的实验研究[J].中华医学杂志,2001,81(19):1194-1197. 被引量:42
  • 5梁云,陆斌,王华菁,李晓冬,崔贞福,郭亚军,刘彦君.p53基因、Fas/FasL在提高肝癌细胞化疗药物敏感性中的作用[J].中华实验外科杂志,2002,19(4):342-344. 被引量:5

共引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部